Log in
NASDAQ:UROV

Urovant Sciences Stock Forecast, Price & News

$10.11
+0.39 (+4.01 %)
(As of 09/18/2020 12:00 AM ET)
Add
Compare
Today's Range
$9.63
Now: $10.11
$10.11
50-Day Range
$7.67
MA: $8.47
$9.72
52-Week Range
$6.55
Now: $10.11
$15.98
Volume85,671 shs
Average Volume75,026 shs
Market Capitalization$315.25 million
P/E RatioN/A
Dividend YieldN/A
Beta1.31
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. The company was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.23 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:UROV
CUSIPN/A
CIKN/A
Phone44-0-20-7400-3347

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($1.90) per share

Profitability

Net Income$-146,740,000.00

Miscellaneous

Employees17
Market Cap$315.25 million
Next Earnings Date11/3/2020 (Estimated)
OptionableNot Optionable
$10.11
+0.39 (+4.01 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive UROV News and Ratings via Email

Sign-up to receive the latest news and ratings for UROV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Urovant Sciences (NASDAQ:UROV) Frequently Asked Questions

How has Urovant Sciences' stock price been impacted by Coronavirus (COVID-19)?

Urovant Sciences' stock was trading at $11.37 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, UROV stock has decreased by 11.1% and is now trading at $10.11.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Urovant Sciences?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Urovant Sciences in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Urovant Sciences
.

When is Urovant Sciences' next earnings date?

Urovant Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Urovant Sciences
.

How were Urovant Sciences' earnings last quarter?

Urovant Sciences Ltd (NASDAQ:UROV) issued its quarterly earnings results on Thursday, August, 13th. The company reported ($0.99) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($1.36) by $0.37.
View Urovant Sciences' earnings history
.

What price target have analysts set for UROV?

1 Wall Street analysts have issued 1-year price targets for Urovant Sciences' shares. Their forecasts range from $28.00 to $28.00. On average, they anticipate Urovant Sciences' share price to reach $28.00 in the next twelve months. This suggests a possible upside of 177.0% from the stock's current price.
View analysts' price targets for Urovant Sciences
.

Who are some of Urovant Sciences' key competitors?

What other stocks do shareholders of Urovant Sciences own?

Who are Urovant Sciences' key executives?

Urovant Sciences' management team includes the following people:
  • Mr. Keith A. Katkin, CEO & Director (Age 48)
  • Ms. Christine G. Ocampo, Chief Accounting Officer and Principal Financial & Accounting Officer (Age 47)
  • Mr. Michael E. McFadden, Chief Commercial Officer of USI (Age 52)
  • Dr. David Hovland, Sr. VP of Global Regulatory Affairs
  • Ms. Nori Ebersole, Sr. VP & Chief HR Officer of USI (Age 56)

When did Urovant Sciences IPO?

(UROV) raised $150 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and Cowen served as the underwriters for the IPO.

What is Urovant Sciences' stock symbol?

Urovant Sciences trades on the NASDAQ under the ticker symbol "UROV."

Who are Urovant Sciences' major shareholders?

Urovant Sciences' stock is owned by a number of institutional and retail investors. Top institutional investors include FMR LLC (2.29%), FMR LLC (2.29%), Alyeska Investment Group L.P. (1.99%), LVW Advisors LLC (0.12%), Personal CFO Solutions LLC (0.11%) and First Trust Advisors LP (0.05%). Company insiders that own Urovant Sciences stock include Andrew Lo, Chemical Co Ltd Sumitomo, Fund V Lp Qvt, Holdings Ltd Dexxon, Kevin Costello, Patrick Machado, Qvt Associates Gp Llc and Sciences Ltd Roivant.
View institutional ownership trends for Urovant Sciences
.

Which major investors are selling Urovant Sciences stock?

UROV stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, and FMR LLC.
View insider buying and selling activity for Urovant Sciences
.

Which major investors are buying Urovant Sciences stock?

UROV stock was bought by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P., Personal CFO Solutions LLC, Vigilare Wealth Management, LVW Advisors LLC, and First Trust Advisors LP. Company insiders that have bought Urovant Sciences stock in the last two years include Andrew Lo, Chemical Co Ltd Sumitomo, Fund V Lp Qvt, Holdings Ltd Dexxon, Kevin Costello, Patrick Machado, Qvt Associates Gp Llc, and Sciences Ltd Roivant.
View insider buying and selling activity for Urovant Sciences
.

How do I buy shares of Urovant Sciences?

Shares of UROV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Urovant Sciences' stock price today?

One share of UROV stock can currently be purchased for approximately $10.11.

How big of a company is Urovant Sciences?

Urovant Sciences has a market capitalization of $315.25 million. The company earns $-146,740,000.00 in net income (profit) each year or ($4.71) on an earnings per share basis. Urovant Sciences employs 17 workers across the globe.

What is Urovant Sciences' official website?

The official website for Urovant Sciences is www.urovant.com.

How can I contact Urovant Sciences?

Urovant Sciences' mailing address is 11-12 STREET JAMES SQUARE SUITE 1 3RD FLOOR, LONDON X0, SW1Y 4LB. The company can be reached via phone at 44-0-20-7400-3347 or via email at [email protected]

This page was last updated on 9/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.